{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "currency": "USD", "regularMarketChangePercent": -5.2177925, "regularMarketPrice": 20.89, "exchange": "NGM", "shortName": "Harrow Health, Inc.", "longName": "Harrow Health, Inc.", "messageBoardId": "finmb_21993612", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "PRE", "firstTradeDateMilliseconds": 1190986200000, "priceHint": 2, "earningsTimestampEnd": 1691755200, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.41, "epsForward": 1.05, "epsCurrentYear": -0.13, "priceEpsCurrentYear": -160.6923, "sharesOutstanding": 30122000, "bookValue": 0.923, "fiftyDayAverage": 22.0406, "fiftyDayAverageChange": -1.1506004, "fiftyDayAverageChangePercent": -0.05220368, "twoHundredDayAverage": 14.61045, "twoHundredDayAverageChange": 6.2795496, "twoHundredDayAverageChangePercent": 0.4297985, "marketCap": 791699648, "forwardPE": 19.895239, "priceToBook": 22.632719, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.7 - Buy", "tradeable": false, "cryptoTradeable": false, "regularMarketChange": -1.1500015, "regularMarketTime": 1684180804, "regularMarketDayHigh": 22.2091, "regularMarketDayRange": "20.55 - 22.2091", "regularMarketDayLow": 20.55, "regularMarketVolume": 848530, "regularMarketPreviousClose": 22.04, "bid": 0.0, "ask": 0.0, "bidSize": 14, "askSize": 8, "fullExchangeName": "NasdaqGM", "financialCurrency": "USD", "regularMarketOpen": 22.1, "averageDailyVolume3Month": 427626, "averageDailyVolume10Day": 640240, "fiftyTwoWeekLowChange": 15.349999, "fiftyTwoWeekLowChangePercent": 2.7707582, "fiftyTwoWeekRange": "5.54 - 28.25", "fiftyTwoWeekHighChange": -7.3600006, "fiftyTwoWeekHighChangePercent": -0.260531, "fiftyTwoWeekLow": 5.54, "fiftyTwoWeekHigh": 28.25, "earningsTimestamp": 1683837900, "earningsTimestampStart": 1691405940, "displayName": "Harrow Health", "symbol": "HROW"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "102 Woodmont Boulevard", "address2": "Suite 610", "city": "Nashville", "state": "TN", "zip": "37205", "country": "United States", "phone": "615 733 4730", "website": "https://www.harrowinc.com", "industry": "Drug Manufacturers\u2014Specialty & Generic", "industryDisp": "Drug Manufacturers\u2014Specialty & Generic", "sector": "Healthcare", "longBusinessSummary": "Harrow Health, Inc., an eyecare pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies. The company offers ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic medicines, including IOPIDINE and MOXEZA; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and MAQ-100, a preservative-free triamcinolone acetonide ophthalmic injection drug candidate. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.", "fullTimeEmployees": 217, "companyOfficers": [{"maxAge": 1, "name": "Mr. Mark L. Baum J.D.", "age": 50, "title": "CEO & Chairman", "yearBorn": 1972, "fiscalYear": 2022, "totalPay": {"raw": 1195141, "fmt": "1.2M", "longFmt": "1,195,141"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 12564608, "fmt": "12.56M", "longFmt": "12,564,608"}}, {"maxAge": 1, "name": "Mr. Andrew R. Boll C.F.A., C.M.A., CFA, CMA", "age": 40, "title": "CFO & Corp. Sec.", "yearBorn": 1982, "fiscalYear": 2022, "totalPay": {"raw": 764386, "fmt": "764.39k", "longFmt": "764,386"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 3642605, "fmt": "3.64M", "longFmt": "3,642,605"}}, {"maxAge": 1, "name": "Mr. John P. Saharek MBA", "age": 62, "title": "Chief Commercial Officer", "yearBorn": 1960, "fiscalYear": 2022, "totalPay": {"raw": 656887, "fmt": "656.89k", "longFmt": "656,887"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 3418270, "fmt": "3.42M", "longFmt": "3,418,270"}}, {"maxAge": 1, "name": "Ms. Jamie  Webb", "title": "Director of Communications & Investor Relations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Dennis E Saadeh Pharm.D.", "title": "Chief of Formulation Strategy", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Larry M. Dillaha M.D.", "age": 59, "title": "Chief Medical Officer", "yearBorn": 1963, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Kim  Barratt", "title": "Chief Talent Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Mark A. Mannebach Ph.D., R.Ph.", "title": "Head of Regulatory Affairs & Pharmacovigilance", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}